Q1 2020

Filed May 8, 2020 · 10-Q · 38 days after period end · 0001104659-20-058786

Q1 2020 · 10-Q

Revenue—

Net Income

-$45.09K

no prior Q1 2019 on file

EPS, diluted—

Operating Income-$87,774—

Operating Cash Flow-$28,750—

Same quarter

no prior Q1 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2020 · filed May 8, 2020 · 38 d after period end

Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR